- Home
- FGNX vs OVID Comparison
FGNX vs OVID Comparison
Compare FGNX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGNX
- OVID
- Stock Information
- Founded
- FGNX 1932
- OVID 2014
- Country
- FGNX United States
- OVID United States
- Employees
- FGNX N/A
- OVID N/A
- Industry
- FGNX Property-Casualty Insurers
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- FGNX Finance
- OVID Health Care
- Exchange
- FGNX Nasdaq
- OVID Nasdaq
- Market Cap
- FGNX 25.2M
- OVID 20.6M
- IPO Year
- FGNX N/A
- OVID 2017
- Fundamental
- Price
- FGNX $10.27
- OVID $1.29
- Analyst Decision
- FGNX
- OVID Strong Buy
- Analyst Count
- FGNX 0
- OVID 4
- Target Price
- FGNX N/A
- OVID $3.13
- AVG Volume (30 Days)
- FGNX 180.5K
- OVID 1.9M
- Earning Date
- FGNX 08-07-2025
- OVID 08-13-2025
- Dividend Yield
- FGNX N/A
- OVID N/A
- EPS Growth
- FGNX N/A
- OVID N/A
- EPS
- FGNX 2.41
- OVID N/A
- Revenue
- FGNX $24,184,000.00
- OVID $6,651,000.00
- Revenue This Year
- FGNX N/A
- OVID $708.13
- Revenue Next Year
- FGNX N/A
- OVID N/A
- P/E Ratio
- FGNX $5.08
- OVID N/A
- Revenue Growth
- FGNX 24.03
- OVID 1070.95
- 52 Week Low
- FGNX $10.10
- OVID $0.24
- 52 Week High
- FGNX $41.25
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- FGNX N/A
- OVID 77.40
- Support Level
- FGNX N/A
- OVID $1.16
- Resistance Level
- FGNX N/A
- OVID $1.30
- Average True Range (ATR)
- FGNX 0.00
- OVID 0.12
- MACD
- FGNX 0.00
- OVID 0.02
- Stochastic Oscillator
- FGNX 0.00
- OVID 90.55
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.